A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
for Advanced Solid Tumor
21 locations incl. Scottsdale
Sponsor: Clasp Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT06778863·Phase 1·Recruiting
Lung oncology Clinical Trials in New York, NY
As of June 2026, 130 paid clinical trials are recruiting for Lung oncology in New York, New York. Lung oncology trials investigate EGFR, ALK, KRAS, and other driver-mutation targeted therapies alongside immunotherapy combinations for non-small cell, small cell, and mesothelioma studies. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Filter results
130 clinical trials for Lung oncology
·Clear filters·↓ Download CSVClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
for Non-Small Cell Lung Cancer
Drug: Ivonescimab
89 locations incl. Chandler
Sponsor: Summit Therapeutics
Sex: All·Age: 18+
Code: NCT06767514·Phase 3·Recruiting
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
for Solid Tumors
Drug: Amivantamab
2 locations incl. New York
Sponsor: ORIC Pharmaceuticals
Sex: All·Age: 18+
Code: NCT06816992·Phase 1·Recruiting
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
for Carcinoma, Non-Small-Cell Lung
1 location in New York
Sponsor: Weill Medical College of Cornell University
Sex: All·Age: 18+
Code: NCT06623656·Phase 2·Recruiting
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
for Small Cell Lung Cancer
1 location in New York
Sponsor: Oncology Center of Biochemical Education And Research
Sex: All·Age: 18 - 85
Code: NCT06717243·Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
for Breast Cancer
17 locations incl. Prescott
Sponsor: Jazz Pharmaceuticals
Sex: All·Age: 18+
Code: NCT06695845·Phase 2·Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
for Carcinoma, Non-Small-Cell Lung
Drug: Amivantamab
150 locations incl. Daphne
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT06667076·Phase 2·Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
for Advanced Solid Tumors
12 locations incl. New Haven
Sponsor: Tubulis GmbH
Sex: All·Age: 18+
Code: NCT06657222·Phase 1, Phase 2·Recruiting
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
for Anatomic Stage IV Breast Cancer AJCC v8
256 locations incl. Tucson
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT06500455·Phase 3·Recruiting
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
for Carcinoma, Non-Small-Cell Lung
16 locations incl. Farmington
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
Sex: All·Age: 18+
Code: NCT06667908·Phase 2·Recruiting
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
for Non-small Cell Lung Cancer
12 locations incl. La Jolla
Sponsor: Daiichi Sankyo
Sex: All·Age: 18+
Code: NCT06644768·Phase 1, Phase 2·Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
for Carcinoma, Non-Small-Cell Lung
Drug: Intismeran autogene
48 locations incl. Gilbert
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06623422·Phase 3·Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
for Non-small Cell Lung Cancer
Drug: Relatlimab
45 locations incl. Mobile
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT06561386·Phase 3·Recruiting
Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers
for Non-Small Cell Lung Cancer
3 locations incl. Miami
Sponsor: Scientific Institute San Raffaele
Sex: All·Age: 18+
Code: NCT06626243·Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
for Metastatic Solid Tumor
17 locations incl. Santa Monica
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06561685·Phase 1·Recruiting
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
for Non Small Cell Lung Cancer
Drug: Osimertinib
146 locations incl. Birmingham
Sponsor: PrECOG, LLC.
Sex: All·Age: 18+
Code: NCT06538038·Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
for Pancreatic Ductal Adenocarcinoma
25 locations incl. Duarte
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06586515·Phase 1·Recruiting
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
for Ovarian Cancer
10 locations incl. Los Angeles
Sponsor: Nammi Therapeutics Inc
Sex: All·Age: 18+
Code: NCT06582017·Phase 1·Recruiting
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
for Non-Small Cell Lung Cancer
7 locations incl. Sacramento
Sponsor: Avistone Biotechnology Co., Ltd.
Sex: All·Age: 18+
Code: NCT06046495·Phase 1·Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
for Metastatic Solid Tumor
Drug: LY4052031
17 locations incl. Duarte
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06465069·Phase 1·Recruiting
A Study of Sacituzumab Govitecan in People With Mesothelioma
for Mesothelioma
7 locations incl. Basking Ridge
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: All·Age: 18+
Code: NCT06477419·Phase 2·Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
for Ovarian Cancer
7 locations incl. Birmingham
Sponsor: Tubulis GmbH
Sex: All·Age: 18+
Code: NCT06303505·Phase 1, Phase 2·Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
for Non-small Cell Lung Cancer
22 locations incl. Birmingham
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Sex: All·Age: 18+
Code: NCT06343402·Phase 1·Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
for Small Cell Lung Cancer
30 locations incl. Springdale
Sponsor: Daiichi Sankyo
Sex: All·Age: 18+
Code: NCT06203210·Phase 3·Recruiting
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
for Ovarian Neoplasms
9 locations incl. Scottsdale
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06400472·Phase 1·Recruiting
A Registry for People With Lung Cancer
for Lung Cancer
15 locations incl. Tucson
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: All·Age: 18+
Code: NCT06424327·Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
for Non-small Cell Lung Cancer
Drug: Osimertinib
36 locations incl. Fountain Valley
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06350097·Phase 3·Recruiting
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
for Oncology
17 locations incl. San Francisco
Sponsor: Nested Therapeutics, Inc
Sex: All·Age: 18+
Code: NCT06326411·Phase 1·Recruiting
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
for Solid Tumor, Adult
12 locations incl. Gilbert
Sponsor: A2 Biotherapeutics Inc.
Sex: All·Age: 18+
Code: NCT06051695·Phase 1, Phase 2·Recruiting
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
for Non-small Cell Lung Cancer
18 locations incl. Duarte
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06218914·Phase 1·Recruiting
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
for Non-Small Cell Lung Cancer
Drug: Cemiplimab
1 location in New York
Sponsor: Icahn School of Medicine at Mount Sinai
Sex: All·Age: 18+
Code: NCT06088771·Phase 1, Phase 2·Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
for Advanced Solid Tumor
13 locations incl. Duarte
Sponsor: Daiichi Sankyo
Sex: All·Age: 18+
Code: NCT06172478·Phase 2·Recruiting
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
for Endometrial Cancer
17 locations incl. Birmingham
Sponsor: SystImmune Inc.
Sex: All·Age: 18+
Code: NCT06293898·Phase 1·Recruiting
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
for Non-small Cell Lung Cancer
9 locations incl. Glendale
Sponsor: Teligene US
Sex: All·Age: 18+
Code: NCT06010329·Phase 2·Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
for Carcinoma, Non-Small-Cell Lung
Drug: LY3537982
91 locations incl. Huntsville
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06119581·Phase 3·Recruiting
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
for Non-small Cell Lung Cancer
Drug: Intismeran autogene
68 locations incl. Anchorage
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06077760·Phase 3·Recruiting
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
for Carcinoma, Non-small-Cell Lung
7 locations incl. Newnan
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
Sex: All·Age: 18+
Code: NCT06116786·Phase 1·Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
for Non-Small Cell Lung Cancer (NSCLC)
Drug: Sotorasib
21 locations incl. Santa Barbara
Sponsor: Amgen
Sex: All·Age: 18 - 100
Code: NCT05920356·Phase 3·Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
for Non-Small Cell Lung Cancer (NSCLC)
Drug: daraxonrasib
21 locations incl. Duarte
Sponsor: Revolution Medicines, Inc.
Sex: All·Age: 18+
Code: NCT06128551·Phase 1, Phase 2·Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
for Non-Small Cell Lung Cancer
Drug: Ivonescimab
76 locations incl. Phoenix
Sponsor: Summit Therapeutics
Sex: All·Age: 18+
Code: NCT05899608·Phase 3·Recruiting